Showing results (181-190 of 198) with videos related to
Sort By:
Pageof 20
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2011
DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapyBenjamin J Moeller, John S Yordy, Michelle D Williams, et al.International Journal of Radiation Oncology, Biology, Physics|July 4, 2012
Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neckJay S Cooper, Qiang Zhang, Thomas F Pajak, et al.Cell Research|January 21, 2015
Tyrosine 370 phosphorylation of ATM positively regulates DNA damage responseHong-Jen Lee, Li Lan, Guang Peng, et al.The New England Journal of Medicine|October 26, 2007
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancerJan B Vermorken, Eva Remenar, Carla van Herpen, et al.Head & Neck|October 22, 2005
Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all?Phillip K Pellitteri, Alfio Ferlito, Alessandra Rinaldo, et al.International Journal of Radiation Oncology, Biology, Physics|February 18, 2004
A multinational, randomized phase III trial of iseganan HCl oral solution for reducing the severity of oral mucositis in patients receiving radiotherapy for head-and-neck malignancyAndy Trotti, Adam Garden, Padraig Warde, et al.Cancer|May 10, 2012
Head and neck carcinoma in the United States: first comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN)K Kian Ang, Amy Chen, Walter J Curran, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicityPhuc Felix Nguyen-Tan, Qiang Zhang, K Kian Ang, et al.Nature Communications|December 6, 2014
miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13Peijing Zhang, Li Wang, Cristian Rodriguez-Aguayo, et al.International Journal of Radiation Oncology, Biology, Physics|October 12, 2016
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129Canhua Xiao, Qiang Zhang, Phuc Felix Nguyen-Tân, et al.Pageof 20